KRAS and rectal cancer: It has been shown that the expression of cyclooxygenase-2, vascular endothelial growth factor, and Raf kinase inhibitor protein and the mutational status of KRAS represent valuable molecular markers that can be used for predicting treatment outcomes in rectal cancer patients [38, 39].